CXCL10
Hemokinski ligand 10 (C-X-C motv) (CXCL10), znan i kao interferonom gama inducirani protein 10 (IP-10) ili maloinducibilni citokin B10 jest citokinski protein od 8,7 kDa, koji je kod ljudi kodiran genom CXCL10 sa hromosoma 4.[5][6] C-X-C motiv hemokin 10 je mali citokin u porodici hemokina CXC.
Aminokiselinska sekvenca
urediDužina polipeptidnog lanca je 98 aminokiselina, а molekulska težina 10.881 Da.[7]
10 | 20 | 30 | 40 | 50 | ||||
---|---|---|---|---|---|---|---|---|
MNQTAILICC | LIFLTLSGIQ | GVPLSRTVRC | TCISISNQPV | NPRSLEKLEI | ||||
IPASQFCPRV | EIIATMKKKG | EKRCLNPESK | AIKNLLKAVS | KERSKRSP |
Struktura
urediTrodimenzijska kristalna struktura ovog hemokina određena je pod tri različita uslova do rezolucije do 1,92Å.[8] Pristupni kodovi Proteinske banke podataka za strukture CXCL10 su 1lv9, 1o7y i 1o80.
Funkcija
urediCXCL10 se izlučuje u nekoliko tipova ćelija, kao odgovor na IFN-γ. Ovi tipovi ćelija uključuju monocite, endotelne ćelije i fibroblaste.[5] Pripisuje mu se nekoliko uloga, kao što je hemoatrakcija za monocite / makrofage, T-ćelije, NK-ćelije i dendritske ćelije, promocija adhezije T-ćelija na endotelne ćelije, antitumorske aktivnosti i inhibicije formiranja kolonija koštane srži i angiogeneze.[9][10] Ovaj hemokin izaziva svoje efekte vezivanjem za hemokinske receprtore CXCR3 na površini ćelije.[11]
Biomarkeri
urediCXCL9, CXCL10 i CXCL11 su se pokazali kao valjani biomarkeri za razvoj srčane insuficijencije i disfunkcije lijeve komore, što ukazuje na potcrtavajući patofiziološki odnos između nivoa ovih hemokina i razvoja nepovoljnog remodeliranja srca.[12] [13]
Klinički značaj
urediOsnovni nivoi CXCL10 u plazmi prije tretmana su povišeni kod pacijenata hronično inficiranih virusom hepatitisa C (HCV) genotipova 1 ili 4 koji ne postižu trajni virusni odgovor (SVR) nakon završetka antivirusne terapije.[14][15] CXCL10 u plazmi sispoljava se u svojoj unutarjetrenoj iRNK, a oboje upečatljivo predviđaju prve dane eliminacije HCV RNK („opadanje prve faze“) tokom terapije interferonom/ribavirinom za sve HCV genotipove.[16] Ovo se također odnosi na pacijente koinficirane HIV-om, gdje nivoi IP-10 prije tretmana ispod 150 pg/mL predviđaju povoljan odgovor i stoga mogu biti korisni u ohrabrivanju ovih inače teško liječivih pacijenata da započnu terapiju.[17] Patogen Leishmania major ima proteazu, GP63, koja cijepa CXCL10, implicirajući CXCL10 u odbrambene mehanizme domaćina određenih unutarćelijskih patogena, poput Leishmania.[18]
Reference
uredi- ^ a b c GRCh38: Ensembl release 89: ENSG00000169245 - Ensembl, maj 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000034855 - Ensembl, maj 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ a b Luster AD, Unkeless JC, Ravetch JV (1985). "Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins". Nature. 315 (6021): 672–6. Bibcode:1985Natur.315..672L. doi:10.1038/315672a0. PMID 3925348. S2CID 4358066.
- ^ Luster AD, Jhanwar SC, Chaganti RS, Kersey JH, Ravetch JV (maj 1987). "Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells". Proceedings of the National Academy of Sciences of the United States of America. 84 (9): 2868–71. Bibcode:1987PNAS...84.2868L. doi:10.1073/pnas.84.9.2868. PMC 304761. PMID 2437586.
- ^ "UniProt, P02778" (jezik: engleski). Pristupljeno 24. 10. 2021.
- ^ Swaminathan GJ, Holloway DE, Colvin RA, Campanella GK, Papageorgiou AC, Luster AD, Acharya KR (maj 2003). "Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine". Structure. 11 (5): 521–32. doi:10.1016/S0969-2126(03)00070-4. PMID 12737818.
- ^ Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (april 2002). "IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking". Journal of Immunology. 168 (7): 3195–204. doi:10.4049/jimmunol.168.7.3195. PMID 11907072.
- ^ Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al. (juli 1995). "Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo". The Journal of Experimental Medicine. 182 (1): 155–62. doi:10.1084/jem.182.1.155. PMC 2192108. PMID 7540647.
- ^ Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD (august 2002). "The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions". Biochemistry. 41 (33): 10418–25. doi:10.1021/bi026020q. PMID 12173928.
- ^ Altara R, Gu YM, Struijker-Boudier HA, Thijs L, Staessen JA, Blankesteijn WM (2015). "Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study". PLOS ONE. 10 (10): e0141394. Bibcode:2015PLoSO..1041394A. doi:10.1371/journal.pone.0141394. PMC 4624781. PMID 26506526.
- ^ Altara R, Manca M, Hessel MH, Gu Y, van Vark LC, Akkerhuis KM, et al. (august 2016). "CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study". Journal of Cardiovascular Translational Research. 9 (4): 302–14. doi:10.1007/s12265-016-9703-3. PMID 27271043. S2CID 41188765.
- ^ Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, et al. (oktobar 2006). "Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection". The Journal of Infectious Diseases. 194 (7): 895–903. doi:10.1086/507307. PMID 16960776.
- ^ Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, et al. (decembar 2006). "IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection". Hepatology. 44 (6): 1617–25. doi:10.1002/hep.21407. PMID 17133471. S2CID 27733803.
- ^ Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, et al. (maj 2010). "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C". Hepatology. 51 (5): 1523–30. doi:10.1002/hep.23509. PMID 20186843. S2CID 205873437.
- ^ Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M (decembar 2010). "IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV". Scandinavian Journal of Infectious Diseases. 42 (11–12): 896–901. doi:10.3109/00365548.2010.498019. PMID 20608766. S2CID 28542340.
- ^ Antonia AL, Gibbs KD, Trahair ED, Pittman KJ, Martin AT, Schott BH, et al. (2019). "Pathogen Evasion of Chemokine Response Through Suppression of CXCL10". Frontiers in Cellular and Infection Microbiology. 9: 280. doi:10.3389/fcimb.2019.00280. PMC 6693555. PMID 31440475.
Dopunska literatura
uredi- Farber JM (mart 1997). "Mig and IP-10: CXC chemokines that target lymphocytes". Journal of Leukocyte Biology. 61 (3): 246–57. doi:10.1002/jlb.61.3.246. PMID 9060447. S2CID 14935171.
- Neville LF, Mathiak G, Bagasra O (septembar 1997). "The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily". Cytokine & Growth Factor Reviews. 8 (3): 207–19. doi:10.1016/S1359-6101(97)00015-4. PMID 9462486.
Vanjskik linkovi
uredi- Lokacija ljudskog genoma C7 i stranica sa detaljima o genu C7 u UCSC Genome Browseru.
- Lokacija ljudskog genoma CXCL10 i stranica sa detaljima o genu CXCL10 u UCSC Genome Browseru.
- P02778